Anti-Dupilumab Antibodies

s

s

s

Antibodies for bioanalysis and drug monitoring of dupilumab and biosimilars

Develop highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for the monoclonal antibody dupilumab (Dupixent) using our range of ready-made antibodies.

• Recombinant antibodies specific to dupilumab
• TrailBlazer Antibody enabling site-directed conjugation and format switching
• Fully human surrogate positive control or calibrator
• Sequence-defined, well-characterized reagents with a secure supply
• Stringent quality control for batch-to-batch consistency

Table 1. Antibodies Specific to Dupilumab.

Anti-Dupilumab Inhibitory Antibodies (Type 1)

Type 1 anti-dupilumab antibodies inhibit the binding of the drug dupilumab to its target, interleukin-4 subunit α (IL-4Rα) receptor. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.

TrailBlazer Antibodies, clones TZA014 AbD47091ad, TZA015 AbD47092ad have a SpyTag2 incorporated at the C-terminus of the antibody heavy chain. In a fast reaction that simply requires mixing at room temperature, these antibodies can form a covalent isopeptide bond to a SpyCatcher reagent, enabling site-directed conjugation or fast conversion to a bivalent Fab or a full-length Ig-like format within an hour.

Anti-Dupilumab Non-Inhibitory Antibodies (Type 2)

The type 2 anti-dupilumab antibodies are paratope specific, non-inhibitory anti-idiotypic antibodies that can be used to measure total dupilumab (free and IL-4Ra bound dupilumab). 

ELISA Protocols to Get You Started

PK Bridging ELISA

Fig. 1. A microtiter plate was coated over night with Human anti-Dupilumab (clone AbD47091ad, TZA014) at a concentration of 1 µg/ml. After washing and blocking with PBST + 5% BSA, 10% human serum was added spiked with increasing concentrations of dupilumab. Detection was performed using HRP-conjugated Human anti-Dupilumab (clone AbD47092pap, TZA015P) at a concentration of 0.5 µg/mL in HISPEC assay diluent and QuantaBlu fluorogenic peroxidase substrate. Data are shown as the mean of three measurements.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple), labeled with HRP.

Anti-Drug Antibody Bridging ELISA

Fig. 2. A microtiter plate was coated over night with dupilumab at a concentration of 1 µg/ml. After washing and blocking with PBST + 5% BSA, PBST with 10% human serum was added spiked with increasing concentrations of Human anti-Dupilumab clone AbD47090ia (HCA383) and AbD47092ia (HCA384). Detection was performed using HRP-conjugated dupilumab at a concentration of 2 µg/ml in HISPEC assay diluent and QuantaBlu fluorogenic peroxidase substrate. Data are shown as the mean of three measurements.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

PK Bridging ELISA Total Drug

Fig. 3. Dupilumab PK bridging ELISA using antibodies TZA016 and TZA017P.

Schematic image of PK bridging ELISA detecting total drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.

Resources

Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.